Rowan Chapman is Head of Healthcare Investing, GE Ventures. She leads the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership. She led the creation of and sits on the boards of the first three Healthcare “NewCos” incubated and launched from GE Ventures, including Evidation Health and Vitruvian Networks.
Prior to joining the ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content.
Before GE, she spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Rowan invested in and held board director and observer roles across a spectrum of healthcare and life science companies, including Adamas (IPO: ADMS), Balance Therapeutics, HealthTap, RainDance, Pacific Biosciences (IPO: PACB), ParAllele (acquired: AFFX), Personalis, Sequenta (acquired: Adaptive) and Verinata (acquired: ILMN). Prior to joining Mohr Davidow Ventures, Rowan was very early employee at Rosetta Inpharmatics (IPO then acquired: MRK) and a Product Marketing Manager at Incyte Genomics.
She holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a postdoctoral fellow at the University of California.
Fund's investment verticals: software, healthcare, energy, advanced manufacturing.